am 251 has been researched along with Cognitive Decline in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, R | 1 |
| Lao, K | 1 |
| Lu, B | 1 |
| Guo, H | 1 |
| Cheng, J | 1 |
| Chen, P | 1 |
| Gou, X | 1 |
1 other study available for am 251 and Cognitive Decline
| Article | Year |
|---|---|
(m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Disease Models, Animal; Endocannabinoids; Hemoglo | 2021 |